New Advances in Chronic Kidney Diseases
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 27
Special Issue Editor
Interests: idiopathic nephrotic syndrome; extracellular vesicles; mitochondria biology; diabetic kidney disease; SGLT2 inhibitors
Special Issue Information
Dear Colleagues,
The prevalence of Chronic Kidney Diseases (CKDs) is still a growing concern worldwide, representing a major public health issue. CKD can progress to end-stage kidney disease, requiring long-term kidney replacement therapies. Driving factors of CKD include hypertension and diabetes, two highly prevalent diseases in the current global population. Understanding the multifaceted pathogenesis of CKD as well as the early detection and the development of novel therapies are key components for expanding our knowledge on CKD. Serum and urinary extracellular vesicles can be a convenient tool for detecting biomarkers of disease progression. Emerging therapeutic agents, e.g., Sodium-glucose co-transporter 2 inhibitors (SGLT2i), show promising results in delaying the development of ESKD. This Special Issue will focus on the advances in CKD research. We encourage researchers to share their latest discoveries on CKD: from biomarkers that could facilitate the early detection of CKD, to gaps in the understanding of the pathophysiology, and finally, pharmacological and/or molecular therapies against CKD. We hope this Special Issue will contribute to better addressing the current challenges in research and clinical practices on CKD.
Dr. Mayra Trentin-Sonoda
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic kidney disease
- biomarkers
- extracellular vesicles
- SGLT2 inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
